Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation

Inclusion Criteria

• •Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or radiation therapy for prostate cancer and who have high risk disease as defined by one of the following:
• •* Node positive disease post-operatively
• •* Capsule involvement
• •* Seminal Vesicles involvement
• •* Gleason score ≥ 8
• •* \>50% of core biopsies that are positive
• •* Clinical Stage T2c and T3
• •* Pre-op PSA \> 15 plus Gleason score of 7
• •* Age greater than 18
• •* ECOG Performance Status 0-1
• •* Serum creatinine \<= 1.5 mg/dl
• •* Granulocyte count \>= 1500/m3, Hemoglobin \> 8.0 g/dl, and platelet count \>= 100,000/m3
• •* Total bilirubin \<= ULN
• •* AST, ALT and Alkaline Phosphatase must be within the range allowing for eligibility.
• •* Signed patient informed consent.
• •* Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for three months thereafter.